<div><p>Objective</p><p>To determine the prognostic factors associated with survival in amyotrophic lateral sclerosis at diagnosis.</p><p>Methods</p><p>This retrospective population-based study evaluated 218 patients treated with riluzole between 2005 and 2014 and described their clinical and demographic profiles after the analysis of clinical data and records from the mortality information system in the Federal District, Brazil. Cox multivariate regression analysis was conducted for the parameters found.</p><p>Results</p><p>The study sample consisted of 132 men and 86 women with a mean age at disease onset of 57.2±12.3 years; 77.6% of them were Caucasian. The mean periods between disease onset and diagnosis were 22.7 months among men and 2...
Objectives: To investigate the effectiveness of riluzole in a long-term follow-up of cohort with spo...
Our objectives were: (1) to identify independent prognostic factors to determine a survival score fo...
Riluzole is to date the only treatment that prolongs amyotrophic lateral sclerosis (ALS) survival. H...
To determine the prognostic factors associated with survival in amyotrophic lateral sclerosis at dia...
OBJECTIVE: To measure survivorship and predictors of prognosis of amyotrophic lateral sclerosis (ALS...
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a disease with a widely varying prognosis. The ma...
Background: Amyotrophic lateral sclerosis (ALS) is a disease with a widely varying prognosis. The ma...
Two cohorts of amyotrophic lateral sclerosis (ALS) patients were identified. One incidence-based coh...
Objective: To evaluate the survival of patients with amyotrophic lateral sclerosis (ALS) in an Itali...
Objective To determine the long-term survival in amyotrophic lateral sclerosis (ALS) and identify pr...
Objective To determine the long-term survival in amyotrophic lateral sclerosis (ALS) and identify pr...
Amyotrophic lateral sclerosis (ALS) has a fatal outcome in about three years, but survival is known ...
OBJECTIVE: To determine the long-term survival in amyotrophic lateral sclerosis (ALS) and identify...
Background: Amyotrophic lateral sclerosis (ALS) is a rare disease in Taiwan; thus, estimation of ALS...
BACKGROUND: Although amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative ...
Objectives: To investigate the effectiveness of riluzole in a long-term follow-up of cohort with spo...
Our objectives were: (1) to identify independent prognostic factors to determine a survival score fo...
Riluzole is to date the only treatment that prolongs amyotrophic lateral sclerosis (ALS) survival. H...
To determine the prognostic factors associated with survival in amyotrophic lateral sclerosis at dia...
OBJECTIVE: To measure survivorship and predictors of prognosis of amyotrophic lateral sclerosis (ALS...
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a disease with a widely varying prognosis. The ma...
Background: Amyotrophic lateral sclerosis (ALS) is a disease with a widely varying prognosis. The ma...
Two cohorts of amyotrophic lateral sclerosis (ALS) patients were identified. One incidence-based coh...
Objective: To evaluate the survival of patients with amyotrophic lateral sclerosis (ALS) in an Itali...
Objective To determine the long-term survival in amyotrophic lateral sclerosis (ALS) and identify pr...
Objective To determine the long-term survival in amyotrophic lateral sclerosis (ALS) and identify pr...
Amyotrophic lateral sclerosis (ALS) has a fatal outcome in about three years, but survival is known ...
OBJECTIVE: To determine the long-term survival in amyotrophic lateral sclerosis (ALS) and identify...
Background: Amyotrophic lateral sclerosis (ALS) is a rare disease in Taiwan; thus, estimation of ALS...
BACKGROUND: Although amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative ...
Objectives: To investigate the effectiveness of riluzole in a long-term follow-up of cohort with spo...
Our objectives were: (1) to identify independent prognostic factors to determine a survival score fo...
Riluzole is to date the only treatment that prolongs amyotrophic lateral sclerosis (ALS) survival. H...